All In Biotech

Drug Trial Radar · NCT07541170

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Oct 6, 2026

Primary completion

Jan 31, 2032

Study completion Mar 31, 2035

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Apr 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the efficacy of divarasib compared with investigator's choice of immunotherapy (pembrolizumab or nivolumab) or observation in participants with resected Kirsten rat sarcoma viral oncogene homolog glycine 12 to cysteine (KRAS G12C)-positive Stage II-IIIB NSCLC, regardless of tumor programmed death-ligand 1 (PD-L1) status, who have not achieved pathologic complete response (pCR) following neoadjuvant chemoimmunotherapy.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • DivarasibDrug

    Divarasib will be administered orally as per the schedule specified in the respective arm.

  • PembrolizumabDrug

    Pembrolizumab will be administered as either a 200 mg intravenous (IV) infusion, every 3 weeks (Q3W) or 395 mg subcutaneous (SC) injection Q3W, for up to 13 cycles (1 cycle = 21 days).

  • NivolumabDrug

    Nivolumab will be administered as either a 480 mg IV infusion, every 4 weeks (Q4W) or 1200 mg SC injection Q4W, for up to 13 cycles (1 cycle = 28 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free Survival (DFS), as Determined by the InvestigatorTime frame: From randomization to disease recurrence or death from any cause (Up to approximately 5 years)

Locations

104 sites in 19 countries. Site status is shown where the registry gives one.

  • Community Cancer Institute (CCI)

    Clovis, California · Recruiting

  • Bay Pines VA Healthcare System

    Bay Pines, Florida · Recruiting

  • Piedmont Cancer Institute, PC

    Atlanta, Georgia · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Profound Research, LLC

    Farmington Hills, Michigan · Recruiting

  • Renown Regional Medical Center

    Reno, Nevada · Recruiting

  • Cancer Care Specialists

    Reno, Nevada · Recruiting

  • San Juan Oncology Associates

    Farmington, New Mexico · Recruiting

  • The James Cancer Hospital and Solove Research Institute

    Columbus, Ohio · Recruiting

  • Baptist Clinical Research Institute

    Memphis, Tennessee · Recruiting

  • Instituto Argentino de Diagnóstico y Tratamiento- IADT

    Capital Federal, Argentina · Recruiting

  • Hospital Britanico

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Centro Oncologico Korben

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Clinica Adventista Belgrano

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Hospital Privado De Comunidad

    Mar del Plata, Argentina · Recruiting

  • Sanatorio de la Mujer

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Jessa Zkh (Campus Virga Jesse)

    Hasselt, Belgium · Recruiting

  • CHU HELORA - Hôpital de Mons - Site Kennedy

    Mons, Belgium · Recruiting

  • Beneficencia Portuguesa de Sao Paulo

    São Paulo, Brazil · Recruiting

  • Cenantron - Centro Avancado de Tratamento Oncologico

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Hospital Moinhos de Vento

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital Sao Lucas - PUCRS

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Clinica de Neoplasias Litoral

    Itajaí, Santa Catarina, Brazil · Recruiting

  • Jewish General Hospital

    Montreal, Quebec, Canada · Recruiting

  • McGill University Health Center

    Montreal, Quebec, Canada · Recruiting

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, China · Recruiting

  • The First People's Hospital of Foshan

    Foshan, China · Recruiting

  • Guangdong General Hospital

    Guangzhou, China · Recruiting

  • The Second Affiliated Hospital of Zhejiang University College

    HangzhouZhejiang, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • Nanjing First Hospital

    Nanjing, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, China · Recruiting

  • Taizhou Hospital Of Zhejiang Province

    Taizhou, China · Recruiting

  • Tianjin Cancer Hospital

    Tianjin, China · Recruiting

  • Anhui Provincial Hospital(The First Affiliated Hospital of USTC)

    Hefei, Anhui, China · Recruiting

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China · Recruiting

  • Shandong Provincial Hospital

    Jinan, Shandong, China · Recruiting

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Recruiting

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.